行情

COLL

COLL

Collegium制药
NASDAQ

实时行情|Nasdaq Last Sale

19.63
-0.20
-1.01%
盘后: 19.63 0 0.00% 16:37 09/20 EDT
开盘
19.57
昨收
19.83
最高
19.73
最低
19.36
成交量
20.03万
成交额
--
52周最高
26.91
52周最低
17.24
市值
6.98亿
市盈率(TTM)
7.22
分时
5日
1月
3月
1年
5年
COLL 与 ZTS:价值投资者现在应该购买哪只股票?
Zacks.com · 11小时前
2021 年第四季度的顶级医药股
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2021.
Investopedia · 6天前
Collegium 宣布在 PAINWeek 2021 全国会议上展示四张海报
STOUGHTON, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that four poster presentations highlighting...
GlobeNewswire · 09/13 12:00
学院将参加即将举行的投资者会议
STOUGHTON, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the fol...
GlobeNewswire · 09/01 20:01
医疗保健行业值得关注的 5 只价值股
What are Value Stocks?
Benzinga · 08/30 14:22
热门股票:中国电动汽车股票受监管担忧拖累; EPIX,MCW 下降; COLL, HHR 提前
Worries about regulation have swirled lately around both Big Tech and Chinese stocks. These conspired to drag down a specific segment of the Chinese tech market on Monday, as China-based
Seekingalpha · 08/16 21:16
午后市场更新:道指转正; Sesen Bio 股价暴跌
Toward the end of trading Monday, the Dow traded up 0.03% to 35,526.99 while the NASDAQ fell 0.34% to 14,771.91. The S&P also rose, gaining 0.02% to 4,468.88.
Benzinga · 08/16 18:32
ASRT, GOCO, AEYE 是中午的搬运工
Gainers: NanoVibronix (NASDAQ:NAOV) +47%. Enlivex Therapeutics (NASDAQ:ENLV) +20%. GoHealth (NASDAQ:GOCO) +16%. Travere Therapeutics (NASDAQ:TVTX) +16%. Collegium Pharmaceutical (NASDAQ:COLL) +16%. Auddia (NASDAQ:AUUD) +15%. AudioEye (NASDAQ:AEYE) +14%. Co...
Seekingalpha · 08/16 16:38
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解COLL最新的财务预测,通过COLL每股收益,每股净资产,每股现金流等数据分析Collegium制药近期的经营情况,然后做出明智的投资选择。
分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测COLL价格均价为26.71,最高价位36.00,最低价为8.00。
EPS
机构持股
总机构数: 241
机构持股: 3,994.28万
持股比例: 112.31%
总股本: 3,556.45万
类型机构数股数
增持
61
183.26万
建仓
15
34.52万
减持
43
78.60万
平仓
19
139.68万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
-0.35%
制药与医学研究
-1.08%
高管信息
Chairman/Director
Michael Heffernan
President/Chief Executive Officer/Director
Joseph Ciaffoni
Chief Financial Officer/Executive Vice President
Colleen Tupper
Executive Vice President/Chief Technology Officer
Alison Fleming
Executive Vice President/General Counsel/Secretary
Shirley Kuhlmann
Executive Vice President
Scott Dreyer
Executive Vice President
Richard Malamut
Lead Director/Independent Director
Gino Santini
Independent Director
Rita Balice-Gordon
Independent Director
Garen Bohlin
Independent Director
John Fallon
Independent Director
John Freund
Independent Director
Gwen Melincoff
Independent Director
Theodore Schroeder
暂无数据
COLL 简况
Collegium Pharmaceutical, Inc.是一家专业制药公司。该公司将抗滥用产品与DETERx平台技术整合用于治疗慢性疼痛及其他疾病,并专注于该产品的开发及商业化业务。该公司的主要候选产品Xtampza ER (Xtampza)是一种抗滥用的缓释型羟考酮(类鸦片处方药)口服制剂。该公司的DETERx平台技术旨在保证高度滥用药物在通过多种滥用及篡改途径使用时的缓释性及安全性,包括将其咀嚼、粉碎或溶解并口服、嗅吸或注射。该公司还专注于COL 195的开发计划。COL 195是用于治疗慢性疼痛的抗滥用缓释氧可酮。该公司正在集中开发COL 171。COL 171用于治疗注意缺陷多动障碍,是临床前期的DETERx抗滥用缓释哌醋甲酯制剂。

微牛提供Collegium Pharmaceutical Inc(NASDAQ-COLL)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的COLL股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易COLL股票基本功能。